Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069

Study Identifier
P12-707
CT.gov Identifier
NCT01346501
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    20 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Participants with RA who continued the one year observational period of study P12-069 and provided informed consent to participate in study P12-707.
    Exclusion Criteria:
    Participants with RA who used biological agents other than adalimumab in the one year observational period of study P12-069.

    Protocol Summary

    The main objective of this study was to determine the ability to maintain response after discontinuation of adalimumab treatment and the secondary objective was to determine radiographic progression in participants participating in the study, including the percentage who displayed minimal progression.

    Study Locations

    No locations found.